HOOKIPA Pharma Inc. reported a net loss of $19.1 million for the three months ended June 30, 2024, compared to a net loss of $18.0 million for the same period in 2023. The company's net loss for the six months ended June 30, 2024, was $4.7 million, a significant decrease from the net loss of $37.7 million reported for the first half of 2023. The company's total non-cancellable obligations under contracts with contract manufacturing organizations (CMOs) were $5.2 million as of June 30, 2024. HOOKIPA recorded $0.2 million in licensing fees related to intellectual property licenses as research and development expenses for the three months ended June 30, 2024, and $2.9 million for the six months ended the same date. The company has also undergone a reverse stock split and appointed new executive officers...Show More

HOOKIPA Pharma Inc. reported a net loss of $19.1 million for the three months ended June 30, 2024, compared to a net loss of $18.0 million for the same period in 2023. The company's net loss for the six months ended June 30, 2024, was $4.7 million, a significant decrease from the net loss of $37.7 million reported for the first half of 2023. The company's total non-cancellable obligations under contracts with contract manufacturing organizations (CMOs) were $5.2 million as of June 30, 2024. HOOKIPA recorded $0.2 million in licensing fees related to intellectual property licenses as research and development expenses for the three months ended June 30, 2024, and $2.9 million for the six months ended the same date. The company has also undergone a reverse stock split and appointed new executive officers, with Dr. Malte Peters as CEO and Terry Coelho as EVP and CFO. HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immunotherapeutics based on its proprietary arenavirus platform. The company's lead oncology program, eseba-vec, is in clinical development for the treatment of HPV16+ head and neck cancers and has received Fast Track and PRIME designations. HOOKIPA also has a program for KRAS mutated cancers, HB-700, which has received IND clearance from the FDA. The company's strategic priority is the development of its oncology portfolio, with plans to initiate the AVALON-1 trial, a randomized Phase 2/3 trial of eseba-vec, in the fourth quarter of 2024. Additionally, HOOKIPA is developing infectious disease therapies in partnership with Gilead Sciences Inc., including programs for Hepatitis B and HIV. As of June 30, 2024, HOOKIPA had cash, cash equivalents, and restricted cash of $77.4 million and does not expect to generate revenue from product sales until regulatory approval is obtained for one or more of its product candidates.